Recent Company News

• 08:04 AM ET Sep 12, 2025
  

  Belite Bio announces completion of Phase 3 DRAGON trial of oral tinlarebant ($68.55, 0.00)

• 08:07 AM ET Sep 08, 2025
  

  Belite Bio announces up to $275M upsized private placement; $125M financing upfront with up to an additional $150M tied to exercise of warrants ($65.74, 0.00)

• 05:09 PM ET May 21, 2025
  

  StreetAccount Sector Summary - Healthcare Post-Market

• 08:18 AM ET Aug 11, 2025
  

  StreetAccount Sector Summary - Healthcare Pre-Market

• 06:02 AM ET Aug 11, 2025
  

  Belite Bio reports Q2 EPS ($0.31) vs FactSet ($0.41) [5 est, ($0.48)-(0.30)] ($69.88, 0.00)

• 08:06 AM ET Aug 07, 2025
  

  Belite Bio announces registered direct offering of $15M ($67.99, 0.00)

• 03:03 AM ET Jul 02, 2025
  

  Belite Bio completes enrollment in Phase 3 PHOENIX trial of Tinlarebant ($57.16, 0.00)

• 03:02 AM ET May 21, 2025
  

  FDA grants Breakthrough Therapy Designation for Belite Bio's tinlarebant to treat Stargardt Disease ($64.81, 0.00)

• 09:03 PM ET May 13, 2025
  

  Belite Bio reports Q1 EPS ($0.45) vs FactSet ($0.35) [5 est, ($0.44)-(0.30)] ($60.89, 0.00)